

1 **SUPPLEMENTARY MATERIAL**

2
3 **Direct evidence for cancer cell-autonomous extracellular protein catabolism in pancreatic**
4 **tumors**

5
6
7
8
9 Shawn M. Davidson^{1,2,3+}, Oliver Jonas^{1,4+}, Mark A. Keibler⁵, Han Wei Hou⁶, Alba Luengo¹, Jared
10 R. Mayers¹, Jeffrey Wyckoff¹, Amanda M. Del Rosario¹, Matthew Whitman¹, Christopher R.
11 Chin¹, Kendall J. Condon², Alex Lammers¹, Katherine A. Kellersberger⁷, Brian K. Stall⁷, Gregory
12 Stephanopoulos⁵, Dafna Bar-Sagi⁸, Jongyoon Han^{6,9}, Joshua D. Rabinowitz¹⁰, Michael J.
13 Cima^{1,11}, Robert Langer^{1,5}, and Matthew G. Vander Heiden^{1,2,3,12*}

14
15
16 1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology,
17 Cambridge, Massachusetts, USA

18 2. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts,
19 USA.

20 3. Broad Institute of MIT and Harvard University, Cambridge, Massachusetts, USA.

21 4. Department of Radiology, Brigham and Women's Hospital and Harvard Medical School,
22 Cambridge, Massachusetts, USA.

23 5. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge,
24 Massachusetts, USA.

25 6. Department of Electrical Engineering and Computer Science, Massachusetts Institute of
26 Technology, Cambridge, Massachusetts, USA.

27 7. Bruker Daltronics, Inc. 40 Manning Rd, Billerica, MA 01821.

28 8. New York University School of Medicine, New York University, New York, New York, USA.

29 9. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge,
30 Massachusetts, USA.

31 10. Department of Chemistry and Integrative Genomics, Princeton University, Princeton, New
32 Jersey, USA.

33 11. Department of Materials Science, Massachusetts Institute of Technology, Cambridge,
34 Massachusetts, USA.

35 12. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School,
36 Boston, Massachusetts, USA.

37
38 +These authors contributed equally to this work.

39
40
41
42
43 * Correspondence:

44 Matthew G. Vander Heiden

45 Koch Institute for Integrative Cancer Research at MIT

46 Cambridge, MA 02139, USA

47 Tel: +1 617 715 4523

48 Fax: +1 617 253 3189

49 E-mail: mvh@mit.edu

50 **SUPPLEMENTARY FIGURE LEGENDS**

51 **Figure S1. Production and purification of msAlbumin and miniaturized plasmapheresis,**
52 **Related to Fig. 1.**

- 53 a. Recombinant mouse serum albumin (MSA) was produced in *P. pastoris*. Supernatant from the
54 culture was collected at 48- and 72-hours post inoculation and analyzed by SDS-PAGE and
55 Coomassie-stain as shown. The predicted molecular weight of MSA is 69kDa.
- 56 b. [¹⁵N]-MSA generated was generated in *P. pastoris*, purified, and a representative analysis of
57 the LVQEVTDFAK tryptic peptide by LC-MS/MS is shown (This preparation corresponds to
58 the infusate used to generate the data presented in Fig. 1).
- 59 c. To determine the extent of albumin amino acid labeling, ¹⁵N-labeled MSA produced in *P.*
60 *pastoris* was subjected to acid hydrolysis and amino acids assessed by GC-MS. The % ¹⁵N
61 isotopomer labeling for the indicated amino acid is shown. (Ala = alanine; Asp = aspartate;
62 Cys = cysteine; Gln = glutamine; Glu = glutamate; Gly = glycine; Ile = isoleucine; Leu =
63 leucine; Lys = lysine; Met = methionine; Phe = phenylalanine; Ser = serine; Thr = threonine;
64 Val = valine).
- 65 d. Schematic representation of a miniaturized multiplexed 4-channel plasmapheresis device
66 fabricated from PDMS as well as a schematic depicting the use of the plasmapheresis device
67 to perform albumin exchange in mice. Blood from the carotid artery is pumped into the device
68 using a miniaturized peristaltic pump, plasma removed, and the cellular component of blood is
69 then re-mixed with labeled albumin and returned to the mouse via a venous catheter
- 70 e. Microscopic image of a single channel in a functioning miniaturized plasmapheresis device
71 showing plasma skimming from arterial blood based on axial migration of red blood cells
72 towards the center of the microchannel at Stage 1, Stage 2, and Stage 3 (see schematic in
73 panel d). The concentrated red blood cells are then mixed with labeled albumin (right panel)
74 prior to reinfusion into mice.

76 **Figure S2. Labeled albumin fate in plasma, lung and muscle of WT and KP animals,**
77 **Related to Fig. 1.**

- 78 a. Representative plasma protein levels from a plasma exchange experiment to deliver labeled
79 mouse serum albumin (MSA). Plasma was collected longitudinally before, during and after the
80 plasma exchange period in WT and KP mice. The time period indicated by the double dagger
81 corresponds to the 30-minute plasma exchange period (n = 5).
- 82 b. Enzyme linked immunoadsorption assay (ELISA) to assess MSA levels in 7-8 week old WT
83 and KP mice, a time point when the KP mice have late stage pancreatic cancer. No significant
84 difference (n.s.) in albumin levels was measured between WT and KP mice (WT n = 11; KP n
85 = 7).
- 86 c. Following plasma exchange of [¹⁵N]-labeled MSA for endogenous MSA in WT and KP mice,
87 the presence of [¹⁵N]-labeled MSA in tissue was determined by analysis of labeled peptides
88 from lungs of animals with pancreatic tumors (KP) or without pancreatic tumors (WT) by LC-
89 MS/MS. No significant difference (n.s.) in albumin levels was measured between WT and KP
90 mice.
- 91 d. The presence of labeled free amino acids in the lungs of WT or KP mice ~12 hours after
92 plasma exchange of [¹⁵N]-labeled MSA for endogenous MSA. Labeled amino acids were
93 determined by GC-MS.
- 94 e. Following plasma exchange of [¹⁵N]-labeled MSA for endogenous MSA in WT and KP mice,
95 the presence of [¹⁵N]-labeled MSA in tissue was determined by analysis of labeled peptides
96 from muscle of animals with pancreatic tumors (KP) or without pancreatic tumors (WT) by LC-
97 MS/MS. No significant difference (n.s.) in albumin levels was measured between WT and KP
98 mice.

99 f. The presence of labeled free amino acids in the muscle of WT or KP mice ~12 hours after
100 plasma exchange of [¹⁵N]-labeled MSA for endogenous MSA. Labeled amino acids were
101 determined by GC-MS
102 (Ala = alanine; Asp = aspartate; Cys = cysteine; Gln = glutamine; Glu = glutamate; Gly =
103 glycine; Ile = isoleucine; Leu = leucine; Lys = lysine; Met = methionine; Phe = phenylalanine;
104 Ser = serine; Thr = threonine; Val = valine). (for panels c-f: * p<0.05; ** p<0.01, *** p<0.001 by
105 unpaired t-test, n.s. differences not significant, n = 5 per genotype).

106

107 **Figure S3. Device placement in autochthonous pancreatic tumors and intravital imaging of**
108 **DQ-BSA in tdTomato-negative pancreatic tumors, Related to Fig 3.**

109 a. Representative hematoxylin and eosin (H&E) staining of devices with reservoirs adjacent to
110 tumor tissue (left, Reservoir #1) and non-tumor tissue (right, Reservoir #2). Dotted black lines
111 indicate the diffusion distance for EIPA observed by MALDI-IMS. Scale bar, 2mm for upper
112 panels (low magnification) and 200µm for lower panels (high magnification).

113 b. Devices containing DQ-BSA were implanted into the pancreas of tomato-negative KP mice
114 with pancreatic tumors. Multiphoton imaging of DQ-BSA fluorescence in the pancreatic tissue
115 of live mice is shown (images are representative of n = 2 mice per genotype with triplicate
116 reservoirs). Scale bar, 50 µm.

117 c. Quantification of macropinocytic index of tomato-negative autochthonous KP tumors based on
118 fluorescence from DQ-BSA as shown in a. The macropinocytic index of MIA PaCa-2 xenograft
119 tumors based on fluorescence from DQ-BSA is shown for comparison (n=5 distinct fields were
120 used to quantify macropinocytic index per condition).

121 Significance differences are noted as $P^* < 0.05$; n.s. not significant, by unpaired t-test.

122

123 **Figure S4. Local depletion of amino acids by EIPA in $Kras^{G12D}$ -driven pancreatic tumors**
124 **and effect of EIPA on amino acid levels in cells in culture. Related to Fig 4.**




- 125 a. Devices containing EIPA were implanted directly into pancreatic tumors of KP mice. The
126 position of the device and direction of the arrow indicate orientation and direction of EIPA
127 delivery (white circle and black arrow, respectively). 24 hours after device implantation, serial
128 sections from the tumor were analyzed by matrix assisted laser desorption ionization coupled
129 to imaging mass-spectrometry (MALDI-IMS). Positive ion mode was used to detect the
130 macropinocytosis inhibitor, EIPA (EIPA diffused approximately 400-500 μ M), and choline, a
131 metabolite not expected to be affected by macropinocytosis inhibition. The range of ion
132 detection corresponding to the heat maps shown for each metabolite is included for each
133 image; scale bar, 2mm. (images are representative of n = 2 KP mice with triplicate reservoirs).
- 134 b. Serial sections from the same tumors described in a. were examined by MALDI-IMS in
135 negative ion mode to assess levels of the amino acids glutamine and histidine. The position of
136 the device (red circle with black arrow showing direction of EIPA delivery) was used to orient
137 the serial sections analyzed in negative ion mode relative to those analyzed in positive ion
138 mode. The location corresponding to EIPA single (see a) is designated by black or white
139 dashed line and full tissue slice is presented for orientation. The relative levels of metabolite
140 concentration corresponding to the heat maps shown for each metabolite is included for each
141 image; scale bar, 2mm (images are representative of n = 2 KP mice with triplicate reservoirs).
- 142 c. Pancreatic cancer cells derived from KP tumors were cultured for 6 hours in media without or
143 with branch chain amino acids (BCAAs), in the presence or absence of 3% albumin, and in
144 the presence of vehicle alone (DMSO) or 20 μ M EIPA as indicated. Relative levels of leucine
145 and valine under each condition as determined by GC-MS are shown.
- 146 d. Pancreatic cancer cells derived from KP tumors were cultured for 6 hours in media containing
147 uniformly labeled ^{15}N and ^{13}C -labeled amino acids in the presence of vehicle alone (DMSO) or

148 20 μ M EIPA as indicated. Total intracellular amino acid levels for each condition as determined
149 by GC-MS are shown (n = 3 individual wells of a 6-well dish, repeated twice).


150 e. Pancreatic cancer cells derived from KP tumors were cultured for 6 hours in media containing
151 uniformly labeled ^{15}N and ^{13}C -labeled amino acids in the presence of vehicle alone (DMSO) or
152 20 μ M EIPA as indicated. Total intracellular levels of ^{15}N -labeled amino acids for each
153 condition as determined by GC-MS are shown (n = 3 individual wells of a 6-well dish,
154 repeated twice).

155 f. Pancreatic cancer cells derived from KP tumors were cultured for 6 hours in media containing
156 uniformly labeled ^{15}N and ^{13}C -labeled amino acids in the presence of vehicle alone (DMSO) or
157 20 μ M EIPA as indicated. Total intracellular levels of ^{13}C -labeled amino acids for each
158 condition as determined by GC-MS are shown (n = 3 individual wells of a 6-well dish,
159 repeated twice).

160 For all panels, significance differences are noted as $P^* < 0.05$ by unpaired t-test.




Davidson and Jonas Supplementary Figure 1




Davidson and Jonas Supplementary Figure 2

a



b

tdTomato -



c

